DGAP-Adhoc

Elanix Biotechnologies AG: CEO informs about planned cash capital increase with indirect subscription rights

DGAP-Ad-hoc: Elanix Biotechnologies AG / Key word(s): Capital Increase
Elanix Biotechnologies AG: CEO informs about planned cash capital increase
with indirect subscription rights

13-Jan-2017 / 14:34 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by
DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Elanix Biotechnologies AG: CEO informs about planned cash capital increase
with indirect subscription rights

THE INFORMATION CONTAINED IN THIS ANNOUNCMENT IS NOT FOR PUBLICATION OR
DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR
JAPAN.

Potsdam, 13 January 2017 - Elanix Biotechnologies AG ("Elanix") announces
that the CEO plans a capital increase against cash contributions granting
an indirect subscription right using the existing Authorised Capital 2015
as early as this quarter. The aim is to strengthen the share capital and to
ensure further growth.

Relevant resolutions have not yet been adopted; however, today the
Supervisory Board was informed by the CEO about his aim to resolve on a
cash capital increase later this month. The cash capital increase shall be
structured in such a way that the capital increase does not require a
prospectus under German legislation. The CEO will inform about the details
of the planned capital increase in a timely manner.

Tomas Svoboda, CEO

Contact/Investor Relations

Maria Widowski
E-mail: [e-mail]
Telephone: [phone]

About Elanix

Elanix Biotechnologies (Frankfurt: ELN) develops and commercializes tissue
regeneration products for acute wound care, dermatological and
gynecological applications, and provides services in cell technologies. The
company was founded in 2013 as a spin-out from the University Hospital of
Lausanne (CHUV), Switzerland, to commercialize a patented progenitor cell
technology. Progenitor cells are fully differentiated yet immunologically
neutral cells that are very potent inducers of tissue growth and healing.
Elanix owns GMP certified Master and Working cell banks with vast
quantities of cells of different cell types.

The Company is headquartered in Nyon, Switzerland, with offices in Potsdam,
and is listed on the Frankfurt stock exchange under the symbol ELN. For
more information and updates, visit www.elanix-biotechnologies.com.

Disclaimer

This publication contains forward-looking statements subject to certain
risks and uncertainties. Actual results may be materially different from
those expressed or implied by such statements due to a variety of risk